Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
For patients with advanced non–small cell lung cancer, genomic profiling of tumors to identify potentially targetable alterations and thereby inform treatment selection is now part of standard care. While molecular analyses are primarily focused on actionable biomarkers associated with regulatory ag...
Main Authors: | Roy S. Herbst, Dara L. Aisner, Joshua R. Sonett, Andrew T. Turk, Joshua L. Weintraub, Neal I. Lindeman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2020.562480/full |
Similar Items
-
RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
by: Takuo Hayashi, et al.
Published: (2021-02-01) -
Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
by: Sai-Hong Ignatius Ou, MD, PhD, et al.
Published: (2020-06-01) -
Significances of RET Fusion Gene in Non-small Cell Lung Cancer
by: Jingjing LIU, et al.
Published: (2013-11-01) -
RET Inhibitors in Non-Small-Cell Lung Cancer
by: Priscilla Cascetta, et al.
Published: (2021-09-01) -
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update
by: Luis Mendoza
Published: (2018-07-01)